SciSparc Advances the Acquisition Process of a Leading Vehicle Importer Company in Israel with the provision of a Bridge Loan of $1.4 million
TEL AVIV, Israel, Jan. 19, 2024 (GLOBE NEWSWIRE) — SciSparc Ltd. (Nasdaq:SPRC) (“Company” or “SciSparc”), a specialty clinical-stage pharmaceutical company focusing on the development of therapies to treat disorders and rare diseases of the central nervous system, announced today that it entered, as lender, into a bridge loan agreement (the “Agreement) with a leading vehicle importer company in Israel, as borrower (the “Target Company”), pursuant to which the Target Company received a bridge loan (the “Bridge Loan”) in the amount of $1.4 million, further to the previously-announced non-binding letter of intent (the “LOI”) for the Company to acquire the Target Company (the “Acquisition”).
Related news for (SPRC)
- Real Assets, Real Shifts: VENU Breaks Ground on New Real Estate Model; Drones, Silicon Carbide, and Quantum Rails Redraw Market Lines
- MoBot alert highlights: NASDAQ: SGLY, NASDAQ: SPRC, NASDAQ: BENF, NASDAQ: EPOW, NASDAQ: VIVK (09/30/25 06:00 AM)
- Don’t Miss Out: MoBot’s Latest Stock Updates 09/30/25 05:00 AM
- Breaking News: MoBot’s Latest Update as of 09/30/25 04:00 AM
- SciSparc: N2OFF Shareholders Approve Merger with SciSparc’s Majority Owned Subsidiary MitoCareX, a Drug Discovery Company Targeting Resistant Cancers Including Pancreatic and Non-Small Cell Lung Cancer